This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

What's in Phil Mickelson's Portfolio? Clorox, Barclays and 3 More He Endorses

Amgen (AMGN) ($119.12) and Pfizer (PFE) (29.56) jointly market Enbrel the drug Phil uses to treat his symptoms of psoriatic arthritis. Amgen is trading above its 200-day SMA at $116.01 after setting an all-time high at $128.96 on march 21. Pfizer is trading below its 200-day SMA at $30.47 after setting a multiyear intraday high at $32.96 on March 6.

Amgen has a positive weekly chart with its five-week MMA at $115.50 while Pfizer has a negative weekly chart with its five-week MMA at $29.97. The technicals thus favor Amgen over Pfizer.

Amgen has a semiannual value level at $102.54 with a monthly risky level at $122.38. Pfizer has an annual value level at $23.35 with semiannual pivots at $28.78 and $29.20 with a monthly risky level at $33.10.

Barclays (BCS) ($16.19) is below its 200-day SMA at $16.62 and has a negative weekly chart with its five-week MMA at $16.57 and 200-week SMA at $15.07. Semiannual; value levels are $13.70 and $12.74 with a quarterly pivot at $16.61 and monthly risky level at $17.06. Good endorsement, sell the stock.

Exxon Mobil (XOM) ($100.23) set an all-time intraday high at $103.45 on May 7 but its weekly chart shifts to negative given a close this week below its five-week MMA at $100.04. A semiannual value level is $91.91 with a semiannual pivot at $100.97 with an annual risky level at $108.71. Use the fuel, sell the stock.

At the time of publication the author held no positions in any of the stocks mentioned.

Follow @Suttmeier

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff

>>Read more: Where to Buy Dad a Cheap iPhone for Father's Day

Richard Suttmeier is the chief market strategist at ValuEngine.com.
2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs